Literature DB >> 11880709

Chemoprevention strategies for non-small cell lung cancer.

Nico van Zandwijk1, Fred R Hirsch.   

Abstract

Among all cancers, lung cancer has the highest rate of mortality in the western world, both in men and women. The poor lung cancer survival rates argue powerfully for new approaches to control this disease, such as chemoprevention, which has been defined as the use of agents that reverse, suppress, or prevent lung carcinogenesis. Over 80% of lung cancers are attributed to tobacco and carcinogens from cigarette smoke, which unquestionably links nicotine addiction and lung cancer. Epidemiologic studies show that not more than 15% of heavy smokers will ultimately develop lung cancer. That 85% of heavy smokers will not develop lung cancer points to differences in susceptibility. Diet and genetically determined factors seem to play an important role in modulating individual susceptibility and are closely linked to the chemoprevention approach. Despite encouraging data from experimental and epidemiologic studies, the evidence for a positive effect in the human situation is still controversial. However, recent developments in molecular biology and increased insight in lung carcinogenesis have led to the potential of more specifically targeted intervention and optimism for new, successful chemopreventive approaches.

Entities:  

Mesh:

Year:  2002        PMID: 11880709     DOI: 10.1097/00001622-200203000-00008

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  2 in total

1.  The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers.

Authors:  Wei Han; Joell J Gills; Regan M Memmott; Stephen Lam; Phillip A Dennis
Journal:  Cancer Prev Res (Phila)       Date:  2009-03-31

2.  Inverse Association between Dietary Intake of Selected Carotenoids and Vitamin C and Risk of Lung Cancer.

Authors:  Martine Shareck; Marie-Claude Rousseau; Anita Koushik; Jack Siemiatycki; Marie-Elise Parent
Journal:  Front Oncol       Date:  2017-02-28       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.